<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01790633</url>
  </required_header>
  <id_info>
    <org_study_id>IMEA 38B</org_study_id>
    <secondary_id>2012-A01681-42</secondary_id>
    <nct_id>NCT01790633</nct_id>
  </id_info>
  <brief_title>Pilot Study Evaluating the Use of Simultaneous HBV, HCV, and HIV Rapid Tests</brief_title>
  <acronym>OPTISCREEN-III</acronym>
  <official_title>Pilot Study Evaluating the Use of Simultaneous HBV, HCV, and HIV Rapid Tests As a Tool for Screening and Access to Care Among At-Risk Populations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mairie de Paris</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>BioMérieux</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pilot, monocentric, prospective, randomized control trial looking at the use of
      rapid tests as a part of normal care. The investigators will be testing for hepatitis B virus
      (HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV). Testing will be
      proposed to all persons seeking care at the Centre d'Accueil, de Soins et d'Orientation from
      the organization Médecin du Monde (CASO, MDM).

      Infection status of participants will be determined by either the standard test (ELISA) or
      rapid test. The choice between tests will be determined randomly.

      The overall goal is to determine the general acceptability and feasibility of rapid tests and
      to see if they can help individuals increase their awareness of infection status when
      compared to longer, routine methods of testing. In addition, results from these tests will
      allow the medical doctor to guide participants to appropriate care. All positive tests will
      be confirmed at a specialized hospital (Hôptial Saint-Antoine, Paris, France) and
      health-specific information will be obtained four months after testing.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Accessibility of Testing Results</measure>
    <time_frame>Evaluated once, up to 4 months after testing</time_frame>
    <description>The number of individuals who obtained test results for HBV, HCV, and/or HIV divided by the total number of tested individuals.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Access to Care</measure>
    <time_frame>Evaluated once, up to 4 months after testing</time_frame>
    <description>The number of individuals seeking specialized care with a complete evaluation of disease severity divided by the total number of seropositive individuals.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Proportion Participating</measure>
    <time_frame>At testing</time_frame>
    <description>The number of individuals accepting to participate in the study divided by the total number of individuals proposed.</description>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of Rapid Test Failures</measure>
    <time_frame>At testing</time_frame>
    <description>The number of rapid tests giving inconclusive results divided by the total number of rapid tests (only available in the rapid test arm).</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">327</enrollment>
  <condition>HIV</condition>
  <condition>Hepatitis B</condition>
  <condition>Hepatitis C</condition>
  <condition>Carcinoma, Hepatocellular</condition>
  <condition>AIDS</condition>
  <arm_group>
    <arm_group_label>Standard testing with ELISA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>HBV, HCV, and HIV infection status determined by enzyme-linked immuno-assay (ELISA).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rapid testing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HBV, HCV, and HIV infection status determined by a rapid test</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>ELISA</intervention_name>
    <description>Enzyme-linked immuno-assay (ELISA) will be used to determine hepatitis B surface antigen (HBsAg), anti-HBsAg antibody (anti-HBs Ab), anti-HCV antibody, and anti-HIV antibody status. Results will be given after test results are available (8-10 days).</description>
    <arm_group_label>Standard testing with ELISA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Rapid Test</intervention_name>
    <description>A rapid test will be performed to determine the subjects' hepatitis B surface antigen (HBsAg, using VIKIA®), anti-HCV antibody (HCV, using OraQuick®), and anti-HIV antibody (HIV, using VIKIA®) status. Results will be given the same day.</description>
    <arm_group_label>Rapid testing</arm_group_label>
    <other_name>VIKIA®, Biomerieux, Marcy-l'Étoile, France</other_name>
    <other_name>OraQuick® HCV Rapid Antibody Test, OraSure Technologies, Inc., Bethlehem, PA, USA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At least 18 years of age

          -  Seeking care at the CASO MDM health care center

          -  Accept to be followed at Saint-Antoine Hospital in the event of a positive test.

        Exclusion Criteria:

          -  Currently under physician's care for viral hepatitis (HBV/HCV-specific) or HIV

          -  Already has been tested (must give any of the following as evidence):

               -  results from HBV and HCV and HIV tests dating at least 3 months back

               -  results from HCV and HIV tests dating at least 3 months back and HBV serology
                  indicating that the participant is immunized against HBV.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julie Bottero, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Saint-Antoine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Consultation d'Accueil, de Soins et d'Orientation (CASO) de Médecins du Monde (MDM)</name>
      <address>
        <city>Paris</city>
        <zip>75011</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.optiscreenb.fr/</url>
    <description>OPTISCREEN B study website</description>
  </link>
  <reference>
    <citation>Bottero J, Boyd A, Gozlan J, Lemoine M, Carrat F, Collignon A, Boo N, Dhotte P, Varsat B, Muller G, Cha O, Picard O, Nau J, Campa P, Silbermann B, Bary M, Girard PM, Lacombe K. Performance of rapid tests for detection of HBsAg and anti-HBsAb in a large cohort, France. J Hepatol. 2013 Mar;58(3):473-8. doi: 10.1016/j.jhep.2012.11.016. Epub 2012 Nov 23.</citation>
    <PMID>23183527</PMID>
  </reference>
  <results_reference>
    <citation>Bottero J, Boyd A, Gozlan J, Carrat F, Nau J, Pauti MD, Rougier H, Girard PM, Lacombe K. Simultaneous Human Immunodeficiency Virus-Hepatitis B-Hepatitis C Point-of-Care Tests Improve Outcomes in Linkage-to-Care: Results of a Randomized Control Trial in Persons Without Healthcare Coverage. Open Forum Infect Dis. 2015 Oct 26;2(4):ofv162. doi: 10.1093/ofid/ofv162. eCollection 2015 Dec.</citation>
    <PMID>26668814</PMID>
  </results_reference>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 7, 2013</study_first_submitted>
  <study_first_submitted_qc>February 11, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 13, 2013</study_first_posted>
  <results_first_submitted>August 25, 2016</results_first_submitted>
  <results_first_submitted_qc>October 19, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 13, 2016</results_first_posted>
  <last_update_submitted>October 19, 2016</last_update_submitted>
  <last_update_submitted_qc>October 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 13, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>rapid test</keyword>
  <keyword>screening</keyword>
  <keyword>ELISA</keyword>
  <keyword>hepatitis B virus</keyword>
  <keyword>hepatitis C virus</keyword>
  <keyword>human immunodeficiency virus</keyword>
  <keyword>access to care</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data will be shared under the following conditions: (1) interested parties must submit a request for data access to the principal investigator and (2) the request is approved by the Scientific Committee.</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Volunteers were recruited from an innercity clinic for persons without healthcare coverage (“Médecins du Monde”, Paris, France). From February 25, 2013 to June 21, 2013, individuals seeking care at the center were asked to participate.</recruitment_details>
      <pre_assignment_details>554 participants were initially screened for eligibility. 150 did not meet inclusion criteria, 16 had a medical condition requiring immediate referral to a specialist, and 61 declined to participate. A total of 327 were randomized.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Standard Testing With ELISA</title>
          <description>HBV, HCV, and HIV infection status determined by enzyme-linked immuno-assay (ELISA).
ELISA: Enzyme-linked immuno-assay (ELISA) will be used to determine hepatitis B surface antigen (HBsAg), anti-HBsAg antibody (anti-HBs Ab), anti-HCV antibody, and anti-HIV antibody status. Results will be given after test results are available (8-10 days).</description>
        </group>
        <group group_id="P2">
          <title>Rapid Testing</title>
          <description>HBV, HCV, and HIV infection status determined by a rapid test
Rapid Test: A rapid test will be performed to determine the subjects' hepatitis B surface antigen (HBsAg, using VIKIA®), anti-HCV antibody (HCV, using OraQuick®), and anti-HIV antibody (HIV, using VIKIA®) status. Results will be given the same day.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="163"/>
                <participants group_id="P2" count="164"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="115"/>
                <participants group_id="P2" count="159"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="48"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did not have serology performed</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>RT failure and no follow-up ELISA</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Standard Testing With ELISA</title>
          <description>HBV, HCV, and HIV infection status determined by enzyme-linked immuno-assay (ELISA).
ELISA: Enzyme-linked immuno-assay (ELISA) will be used to determine hepatitis B surface antigen (HBsAg), anti-HBsAg antibody (anti-HBs Ab), anti-HCV antibody, and anti-HIV antibody status. Results will be given after test results are available (8-10 days).</description>
        </group>
        <group group_id="B2">
          <title>Rapid Testing</title>
          <description>HBV, HCV, and HIV infection status determined by a rapid test
Rapid Test: A rapid test will be performed to determine the subjects' hepatitis B surface antigen (HBsAg, using VIKIA®), anti-HCV antibody (HCV, using OraQuick®), and anti-HIV antibody (HIV, using VIKIA®) status. Results will be given the same day.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="162"/>
            <count group_id="B2" value="162"/>
            <count group_id="B3" value="324"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.0" spread="12.2"/>
                    <measurement group_id="B2" value="37.0" spread="12.2"/>
                    <measurement group_id="B3" value="37.6" spread="12.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="63"/>
                    <measurement group_id="B3" value="123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="102"/>
                    <measurement group_id="B2" value="99"/>
                    <measurement group_id="B3" value="201"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HBV prevalence of birth country</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Low (&lt;2.0%)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intermediate (2.0%-8.0%)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High (&gt;8.0%)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="133"/>
                    <measurement group_id="B2" value="124"/>
                    <measurement group_id="B3" value="257"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>No health insurance plan</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="162"/>
                    <measurement group_id="B2" value="162"/>
                    <measurement group_id="B3" value="324"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Accessibility of Testing Results</title>
        <description>The number of individuals who obtained test results for HBV, HCV, and/or HIV divided by the total number of tested individuals.</description>
        <time_frame>Evaluated once, up to 4 months after testing</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Standard Testing With ELISA</title>
            <description>HBV, HCV, and HIV infection status determined by enzyme-linked immuno-assay (ELISA).
ELISA: Enzyme-linked immuno-assay (ELISA) will be used to determine hepatitis B surface antigen (HBsAg), anti-HBsAg antibody (anti-HBs Ab), anti-HCV antibody, and anti-HIV antibody status. Results will be given after test results are available (8-10 days).</description>
          </group>
          <group group_id="O2">
            <title>Rapid Testing</title>
            <description>HBV, HCV, and HIV infection status determined by a rapid test
Rapid Test: A rapid test will be performed to determine the subjects' hepatitis B surface antigen (HBsAg, using VIKIA®), anti-HCV antibody (HCV, using OraQuick®), and anti-HIV antibody (HIV, using VIKIA®) status. Results will be given the same day.</description>
          </group>
        </group_list>
        <measure>
          <title>Accessibility of Testing Results</title>
          <description>The number of individuals who obtained test results for HBV, HCV, and/or HIV divided by the total number of tested individuals.</description>
          <units>proportion of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="162"/>
                <count group_id="O2" value="162"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.642"/>
                    <measurement group_id="O2" value="0.981"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>We approached our analysis as a pilot study with the aim of addressing feasibility. 70% of patients seen at the MDM clinic obtain a test result with standard serology. Assuming a 20% increase in infection awareness and type 1 error of 0.05, and power of at least 0.9, a minimum of 82 participants per group would be needed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value adjustments for multiple comparisons were not necessary. Significance was determined using P &lt; 0.05</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Access to Care</title>
        <description>The number of individuals seeking specialized care with a complete evaluation of disease severity divided by the total number of seropositive individuals.</description>
        <time_frame>Evaluated once, up to 4 months after testing</time_frame>
        <population>Analysis includes only participants with positive HIV, HBV, and/or HCV results.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Testing With ELISA</title>
            <description>HBV, HCV, and HIV infection status determined by enzyme-linked immuno-assay (ELISA).
ELISA: Enzyme-linked immuno-assay (ELISA) will be used to determine hepatitis B surface antigen (HBsAg), anti-HBsAg antibody (anti-HBs Ab), anti-HCV antibody, and anti-HIV antibody status. Results will be given after test results are available (8-10 days).</description>
          </group>
          <group group_id="O2">
            <title>Rapid Testing</title>
            <description>HBV, HCV, and HIV infection status determined by a rapid test
Rapid Test: A rapid test will be performed to determine the subjects' hepatitis B surface antigen (HBsAg, using VIKIA®), anti-HCV antibody (HCV, using OraQuick®), and anti-HIV antibody (HIV, using VIKIA®) status. Results will be given the same day.</description>
          </group>
        </group_list>
        <measure>
          <title>Access to Care</title>
          <description>The number of individuals seeking specialized care with a complete evaluation of disease severity divided by the total number of seropositive individuals.</description>
          <population>Analysis includes only participants with positive HIV, HBV, and/or HCV results.</population>
          <units>proportion of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.938"/>
                    <measurement group_id="O2" value="0.900"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7</p_value>
            <p_value_desc>P-value adjustments for multiple comparisons were not necessary. Significance was determined using P &lt; 0.05</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Proportion Participating</title>
        <description>The number of individuals accepting to participate in the study divided by the total number of individuals proposed.</description>
        <time_frame>At testing</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Screened for Eligibility</title>
            <description>Individuals who were screened for eligibility, prior to being considered for randomization.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion Participating</title>
          <description>The number of individuals accepting to participate in the study divided by the total number of individuals proposed.</description>
          <units>proportion of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="554"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.890"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Proportion of Rapid Test Failures</title>
        <description>The number of rapid tests giving inconclusive results divided by the total number of rapid tests (only available in the rapid test arm).</description>
        <time_frame>At testing</time_frame>
        <population>Only patients randomized to the rapid testing arm.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Testing With ELISA</title>
            <description>HBV, HCV, and HIV infection status determined by enzyme-linked immuno-assay (ELISA).
ELISA: Enzyme-linked immuno-assay (ELISA) will be used to determine hepatitis B surface antigen (HBsAg), anti-HBsAg antibody (anti-HBs Ab), anti-HCV antibody, and anti-HIV antibody status. Results will be given after test results are available (8-10 days).</description>
          </group>
          <group group_id="O2">
            <title>Rapid Testing</title>
            <description>HBV, HCV, and HIV infection status determined by a rapid test
Rapid Test: A rapid test will be performed to determine the subjects' hepatitis B surface antigen (HBsAg, using VIKIA®), anti-HCV antibody (HCV, using OraQuick®), and anti-HIV antibody (HIV, using VIKIA®) status. Results will be given the same day.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Rapid Test Failures</title>
          <description>The number of rapid tests giving inconclusive results divided by the total number of rapid tests (only available in the rapid test arm).</description>
          <population>Only patients randomized to the rapid testing arm.</population>
          <units>proportion of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="162"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.074"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Standard Testing With ELISA</title>
          <description>HBV, HCV, and HIV infection status determined by enzyme-linked immuno-assay (ELISA).
ELISA: Enzyme-linked immuno-assay (ELISA) will be used to determine hepatitis B surface antigen (HBsAg), anti-HBsAg antibody (anti-HBs Ab), anti-HCV antibody, and anti-HIV antibody status. Results will be given after test results are available (8-10 days).</description>
        </group>
        <group group_id="E2">
          <title>Rapid Testing</title>
          <description>HBV, HCV, and HIV infection status determined by a rapid test
Rapid Test: A rapid test will be performed to determine the subjects' hepatitis B surface antigen (HBsAg, using VIKIA®), anti-HCV antibody (HCV, using OraQuick®), and anti-HIV antibody (HIV, using VIKIA®) status. Results will be given the same day.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="162"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="162"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Single-center pilot study, possibly reducing generalizability; small number of participants and infected individuals may have decreased power to detect differences in linkage-to-care; not all rapid tests were approved for routine use in France.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Julie Bottero</name_or_title>
      <organization>Service des maladies infectieuses et tropicales - Hôpital Saint-Antoine</organization>
      <phone>+33 1 49 28 04 24</phone>
      <email>julie.bottero@aphp.fr</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

